REGENXBIO Inc. (RGNX)

NASDAQ • Healthcare

$6.68

-$0.49 (-6.8%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$7.03

Previous Close$6.68

Day Range$6.63 - $7.08

Avg. Volume (3M)1.4M

Market Cap$440.9M

52 Week Range

$5.46$16.19

Next EarningsIn 11 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$108M100%

Gross Profitminus cost of goods$106.9M99%

Operating Incomeminus R&D and overhead$29.2M27%

Net Incomeminus taxes and the rest$22.7M21%

In plain terms: out of every $100 in revenue, REGENXBIO Inc. keeps $21 as net profit.

Fundamentals & Financials

Revenue (TTM)

$174.4M

Net Income (TTM)

-$196.4M

EPS (TTM)

-$3.79

ROA (TTM)

-50.81%

Current Ratio

2.86

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-22.1%Q3 2025-$1.38

+13.0%Q4 2025-$1.2

-28.7%Q1 2026-$1.3

-26.5%Q2 2026-$1.72

+446.2%Q3 2026$0.43

Nov 5

in 11 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Next report — what to expect

REGENXBIO Inc. (RGNX) reports earnings on November 5, 2026. Wall Street expects EPS of -$1.208 on revenue of $15.9 million. For trailing context, revenue grew +405.7% year over year last quarter. The company has beaten EPS in 3 of its 8 most recent quarters, with attention on updates that could shift revenue timing.

View full earnings history

About REGENXBIO Inc.

REGENXBIO Inc. is a NASDAQ-listed biotechnology company that develops gene therapy candidates designed to introduce genes into cells, with therapies intended to correct genetic deficiencies or prompt cells to produce therapeutic proteins or antibodies. The company generated $170.4 million in FY2025 revenue.

Name

REGENXBIO Inc.

CEO

Curran Simpson

Website

www.regenxbio.com

Industry

Healthcare

Year Founded

2008

Employees

371

Today's Snapshot

AI-generated

RGNX closed 6.8% below yesterday's close, in line with a weaker sector. Earnings are due from RGNX on 5 November.

Trading Volume

Above 10d avg 1.4M

1.4M

vs S&P 500 Today

Strong Underperformance

-6.31%

Updated: October 23, 2026 at 20:20 UTC

RGNX Headlines

REGENXBIO maps 2026 gene therapy milestones

March 6, 2026

6 min read

View All News

Technical Indicators

1 Buy2 Neutral5 Sell

RGNX displays mixed technicals with a low ADX signaling little trend and short-term momentum skewed bearish: RSI sits in the 30s and CCI is deeply negative, while stochastic and Williams readings point to oversold conditions. The stock trades well below its short-, medium- and long-term moving averages, leaving it under longer-term pressure, and the pivot near 7.15 sits above the market as resistance. ATR shows relatively high percentage volatility and OBV is negative, reflecting weak volume dynamics. Technical takeaway: Neutral — oversold short-term signals coexist with persistent weakness versus longer-term averages.

All signals